Elicera Therapeutics (Q4 review): Important readout ahead - Redeye

Redeye returns with an update following Elicera’s Q4 earnings release. The numbers offered few surprises, which is typical for a pre-revenue biotech. What stands out is the upcoming data from the CARMA-study with ELC-301, expected in Q2.

Länk till analysen i sin helhet: https://www.redeye.se/research/1150444/elicera-therapeutics-q4-review-important-readout-ahead?utm_source=finwire&utm_medium=RSS